Medpace Holdings, Inc.
0.26 %
-25.04 %
Yet to be announced
Company Overview
Medpace Holdings, Inc. is a clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company helps clients in the design and execution of clinical trials, regulatory submissions, and various laboratory testing services to support drug and medical device development.
Revenue Sources
PassBased on the company's SEC filings and business model, Medpace's revenue comes from providing clinical research and development services. These services are halal as they contribute to the advancement of medical knowledge and healthcare. The company does not derive income from prohibited sources such as alcohol, gambling, or other haram activities.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| March 31, 2025 | $558.57m | $445.05m | - | - | 0.00% | 0.00% |
| Dec. 31, 2024 | $536.59m | $411.21m | - | - | 0.00% | 0.00% |
| Sept. 30, 2024 | $533.32m | $421.04m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $528.1m | $422.95m | - | - | 0.00% | 0.00% |
Analysis of the financial data for the past four quarters shows that Medpace has reported zero interest income and zero interest expense. This indicates that interest-bearing transactions are not a material part of their business model or operations.
Operational Ethics
PassBased on available information from SEC filings and company disclosures, there is no evidence of significant ongoing associations with entities involved in human rights violations. The company operates primarily in North America, Europe, and Asia, but there are no documented substantial ties to the state of Israel or direct involvement with the Chinese Communist Party.
Comments